**Title:** Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine

**Short title**: Bromocriptine and heart valve disease

**Authors:** Marianne F. Clausen MB1

Rasmus Rørth MD1

Christian Torp-Pedersen MD DMSc2

Lucas Malta Westergaard MB1

Peter E. Weeke MD PhD1

Gunnar Gislason MD PhD3

Lars Køber MD DMSc1

Emil Fosbøl MD PhD1

Søren Lund Kristensen MD PhD1

**Affiliations:** 1Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 2Department of Clinical Investigation and Cardiology, Nordsjaellands Hospital, Hilleroed, Denmark; 3Department of Cardiology, Gentofte/Herlev University Hospital, Copenhagen, Denmark;

**Correspondence:** Søren Lund Kristensen, MD PhD

 Department of Cardiology, Rigshospitalet

 Blegdamsvej 9, Copenhagen 2100, Denmark

 Tel: +45 28694385

 E-mail: slk@heart.dk

**Keywords:** Bromocriptine, ergot-derived dopamine agonist, heart valve disease, hyperprolactinemia

## Supplementary Appendix

Supplementary Appendix Table 1: ICD-10 and -8 codes used to identify in and outpatient diagnoses, and procedure codes according to the Nordic Medico-Statistical Committee nomenclature:

|  |
| --- |
| The Danish National Patient Register:Inclusion diagnoses:Hyperprolactinaemic disorders (BKHH, DN645A, E220, N62, E282, N644, E221, D352, D443)Exclusion diagnoses: Rheumatic heart disease (DI05-DI09 (390-398)) Rheumatic fever (DI00-DI02) Cardiomyopathies or Chorda tendinae rupture (DI42, DI43, DI511 (425)) Non-rheumatic heart valve diseases (DI34-DI37 (424)) Congenital heart diseases (DQ23, DQ24 (74660-74669)) Endocarditis (DI33, DI38, DI39 (421)) Parkinson’s disease (DG20-DG22 (34299, 06600)) Heart failure (DI42, DI50, DJ819, DI110, DI130, DI132 (425, 428, 4270, 4271))Outcomes: Heart valve disease - diagnosis (DI34, DI35, DI36, DI37) Valvular heart surgery - procedure (KFGA, KFGC-E, KFGW, KFJE, KFJF, KFK, KFM) Comorbidities: Ischemic heart disease (DI20-DI25 (410-414)) Acute myocardial infarction (DI21-DI22 (410)) Atrial fibrillation (DI48 (42793, 42794)) Ischemic stroke (DI63-DI64 (430-434, 436)) Transient Ischemic Attack (DG45 (435)) Embolism (DI74 (444)) Pulmonary embolism (DI26 (450)) Deep vein thrombosis (DI801-DI803, DI808, DI809, DI821-DI823, DI828, DI829 (45100, 45108, 45109, 45190, 45199, 45300, 45302-45304, 45309)) Atherosclerosis (DI70 (440)) Coagulopathy (DD66-DD69 (286)) Bleeding (DI60-DI62, DN02, DR31, DR04, DD62, DH052A, DG951A, DS368D, DK298A, DK228F, DI864A, DK638B, DK638C, DK638F, DK868G, DI312, DH356, DH431, DH450, DS064-DS066, DJ942, DD500, DK250, DK252, DK254, DK256, DK260, DK262, DK264, DK266, DK270, DK272, DK274, DK276, DK280, DK282, DK284, DK286, DK290, DK661, DK921, DK922, DI850)  Diabetes (DE10-DE14 (250)) Alcohol (DF10, DK70, DE52, DT51, DK860, DE244, DG312, DI426, DO354, DZ714, DG621, DG721, DK292, DL278A (291, 303, 57109, 57110, 57710)) Chronic Obstructive Lung Disease (DJ42-DJ44 (490-492)) Malignancy (DC00-DC97 (140-209)) Abnormal liver function (DB15-DB19, DK70-DK77, DC22, DI982, DZ944, DD684C, DQ618A (571-573, 155, 070)) Chronic renal disease (DN02-DN08, DN11-DN12, DN14, DN18-DN19, DN26, DM321B, DN158-DN160, DN162, DN153, DN164, DN168, DQ612, DQ613, DQ615, DQ619, DE102, DE112, DE132, DE142, DI120, DM300, DM313, DM319, DT858, DT859, DZ992 (403, 404, 581-584)) |

Supplementary appendix Table 2: ATC codes for evaluated pharmacotherapy

Inclusion criteria

 Bromocriptine (N04BC01)

Exclusion criteria

 Fenfluramine (A08AA02)

 Dexfenfluramine (A08AA04)

 Ergotamine (N02CA02)

 Levodopa (N04BA01-06)

 Cabergoline (G02CB03)

 Quinagolide (G02CB04)

 Pergolide (N04BC02)

Baseline medication:

 Beta-blockers (C07, C09BX)

 Calcium channel blockers (C08, C07F, C09BB, C09DB)

 RAS inhibitors (C09)

 Vasodilators (C02DB, C02DD, C02DG)

 Antiadrenergic drugs (C02A, C02B, C02C)

 Thiazides (C03A, C07B, C07D, C09XA52, C03EA01)

 Loop diuretics (C03C, C03EB01, C03EB02)

 Spironolactone (C03DA01)

 Diuretics, combination (C07C, C08G, C03B, C09BA, C09DA)

 Digoxin (C01AA05)

 Statins (C10AA)

 Antidiabetics (A10)

 Aspirin (B01AC06)

 ADP inhibitors (B01AC04, B01AC22, B01AC24)

 Anticoagulants (B01AA, B01AE, B01AF)

 Hypertension: Defined as the use of 2 or more of following drug agents: beta blockers, calcium channel blockers, RAS inhibitors, vasodilators, antiadrenergic drugs, thiazides, loop diuretics, spironolactone, diuretics in combination